EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment Framework

Tarek A Hammad, Justine Rochon, Salman Afsar, Sue H Lee, Dona M Ely, Neda Hassanpour, Andrew Bate

Drug Safety · 2026-12 · 49 (12) · 1547-1556

DOI: 10.1007/s40264-026-01700-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Safety, online erschienen am 15.07.2026. Verfasst von Tarek A Hammad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Patient Safety and Pharmacovigilance (PSPV), Takeda Development Center Americas, Inc., Cambridge, USA. Tarek.hammad@takeda.com. Hauptthemen laut MEDLINE: Artificial Intelligence, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The safety signal assessment process evaluates the potential causal association between a medicinal product and a specific adverse event by integrating multiple streams of evidence. Existing causality assessment methods remain challenged by the considerable manual effort involved and by decision variability, even when drawing on the same underlying domains of evidence. This work addresses the need in contemporary pharmacovigilance for a more efficient and harmonized approach to signal confirmation that preserves scientific rigor while mitigating the limitations of the current assessment processes. To address this need, the article describes design considerations for an artificial intelligence (AI)-enabled, integrated approach for safety signal causality assessment, referred to as Signal Confirmation through Omnichannel Pharmacovigilance Evidence (PV-SCOPE). As a conceptual proof-of-principle, the proposed approach describes how the Hammad-Afsar holistic causality assessment framework could be operationalized through multimodal evidence integration and structured approach, while preserving the central role of clinical and scientific reasoning in causality assessment. Because the AI workflow is presented as a design-oriented framework rather than a completed or validated model, the article focuses on architectural logic, governance, and validation and regulatory requirements rather than reporting performance results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligencePharmacovigilanceDrug-Related Side Effects and Adverse ReactionsAdverse Drug Reaction Reporting SystemsJudgmentHumansCausality

Autor:innen und Institutionen

  • Patient Safety and Pharmacovigilance (PSPV), Takeda Development Center Americas, Inc., Cambridge, USA. Tarek.hammad@takeda.com.
  • R&D Data and Quantitative Sciences, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
  • Worldwide Patient Safety, Bristol Myers Squibb, Princeton, USA.
  • Patient Safety and Pharmacovigilance (PSPV), Takeda Development Center Americas, Inc., Cambridge, USA.
  • R&D Technology Services, Takeda Development Center Americas, Inc., Cambridge, USA.
  • Safety Innovation and Analytics, GSK, Philadelphia, USA.

Zitieren

APA

Hammad, T. A., Rochon, J., Afsar, S., Lee, S. H., Ely, D. M., Hassanpour, N., & Bate, A. (2026). Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment Framework. Drug Safety, 49(12), 1547-1556. https://doi.org/10.1007/s40264-026-01700-7

Vancouver

Hammad TA, Rochon J, Afsar S, Lee SH, Ely DM, Hassanpour N, et al. Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment Framework. Drug Safety. 2026;49(12):1547-1556. doi:10.1007/s40264-026-01700-7

BibTeX
@article{Hammad2026,
  author = {Hammad, Tarek A and Rochon, Justine and Afsar, Salman and Lee, Sue H and Ely, Dona M and Hassanpour, Neda and Bate, Andrew},
  title = {Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment Framework},
  journal = {Drug Safety},
  year = {2026},
  volume = {49},
  number = {12},
  pages = {1547--1556},
  doi = {10.1007/s40264-026-01700-7}
}
Kostenlos starten →